Viewing Study NCT01805557

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2026-06-22 @ 9:48 PM
Study NCT ID: NCT01805557
Status: COMPLETED
Last Update Posted: 2022-06-08
First Post: 2013-03-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Sponsor: Fondazione Italiana Linfomi - ETS
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B-cell Lymphoma Refractory View
None Diffuse Large B-cell Lymphoma Recurrent View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Diffuse Large B-cell Lymphoma (DLBCL) View
None Bortezomib View